News and Announcements
TAIM Investments continues out-performance in March and overall exceptional Q1 for 2019
- Published April 10, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The Australian sharemarket continued to perform strongly during March, with the ASX200 Accumulation Index closing out the first quarter of 2019 with a +10.8% gain, reversing the slump of the previous quarter. Easing global trade tensions and reduced expectations of interest rate tightening have done much to buoy investor sentiments.
Our Momentum Fund again produced a solid result, returning +2.1% for March and outperforming its benchmark by +1.4% for the month.
Our Leveraged Fund also produced a strong positive return, gaining +4.7% during March. Since inception (18 months) this fund has now provided initial investors with a return of +26.9%, rebounding strongly from the lows of late 2018.
The TAIM Funds have experienced only one down week so far this year and have closed out an exceptional first quarter, with our Momentum Fund gaining +18.6% and our Leveraged Fund gaining +32.9% for the three month period.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
